Press Release



ABIONYX Pharma Announces Landmark Validation:
A Study published in NATURE Confirms Genetic Causality of
Apolipoprotein A-I (ApoA-I) in Sepsis

A Global Turning Point for Critical Care Medicine


Toulouse, FRANCE, Fullerton, CA, USA, October 21, 2025, 6:00 p.m. CEST - ABIONYX Pharma,
(FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the world's only recombinant apoA-I,
today announced the publication of a ground breaking study in Scientific Reports in Nature Portfolio
titled “Plasma apolipoprotein A-I is a causal protective factor in sepsis.”

This landmark publication provides, for the first time, genetic proof of a causal linkage between higher
plasma ApoA-I levels and a lower incidence of sepsis and lower mortality in patients who do develop
sepsis — a breakthrough that reshapes the scientific and therapeutic landscape of one of medicine’s
deadliest conditions. At the same time, the publication provides genetic validation of the well-studied
mechanism of apoA-I’s beneficial impact on sepsis – the sequestration of the bacterial lipid toxin, LPS,
which is responsible for the manifestations of sepsis. The report provides evidence that apoA-I is also
effective in reducing mortality in Gram positive sepsis driven by the bacterial toxin lipoteichoic acid.
Importantly, the findings were replicated across three independent data sets, including both Caucasian
and Asian sepsis sufferers. This publication adds to the evidence from a previous publication by Trinder
et al which provided genetic validation of similar benefits of higher HDL on sepsis incidence and
mortality. The structural protein which defines HDL is apoA-I.

First Genetic Evidence of Causality

The study analyzed 442,601 participants from the UK Biobank, including 11,643 sepsis cases, and
validated the findings across two large international cohorts, Europe (The Vasopressin and Septic
Shock Trial VASST) and Japan (Chiba Cohort). Results demonstrate that each standard deviation
increase in plasma apoA-I levels reduces the incidence of sepsis by 13% (OR = 0.87, 95% CI [0.86–0.89],
P = 7.4 × 10⁻⁴⁴) and 28-day mortality by 27% (OR = 0.73, 95% CI [0.71–0.76], P = 8.2 × 10⁻⁴⁰).
Using Mendelian randomization, the researchers confirmed that this protective effect is causal and
independent of other lipid fractions (HDL-C, LDL-C, triglycerides) (adjusted OR = 0.71, 95% CI [0.65–
0.77], P = 2.4 × 10⁻²⁰).
Mechanistically, higher apoA-I levels were linked to a reduction in circulating endotoxin (LPS) levels
(logOR = -0.23, P = 9.1 × 10⁻⁸¹), reinforcing apoA-I’s role as a central modulator of inflammatory
response and innate immunity in sepsis.
1/2
A Paradigm Shift in Sepsis Therapeutics

Sepsis — a life-threatening dysregulated immune response responsible for over 11 million deaths each
year worldwide and the third leading cause of in-hospital death in the US — has long lacked any
genetically validated therapeutic target or any specific therapy.
This study positions apoA-I as the first proven causal protective factor in sepsis, transforming the
scientific foundation for drug development in critical care.
For ABIONYX Pharma, whose proprietary technology enables scalable GMP production of
recombinant apoA-I and next-generation HDL mimetics, this discovery represents a new scientific
validation and strategic inflection point after the recently published phase IIa study RACERS where
CER-001 improved clinical outcomes in sepsis patients.

“This publication is a game-changer,” said Dr. Rob SCOTT, MD, Head of R&D and CMO of ABIONYX
Pharma. “ For decades, the field of sepsis has searched for a causal target. The mechanistic effect of
apoA-I and HDL has been well documented over the last 40 years but now, this new genetic validation
provides proof that apoA-I is a major factor determining whether patients develop sepsis and whether
they survive it.

This major publication in Nature is a significant milestone that reinforces the scientific and strategic
value of the company in ongoing discussions with a leading partner in sepsis.


Reference
Campbell KR et al. (2025) Plasma apolipoprotein A-I is a causal protective factor in sepsis. Scientific
Reports 15, Article 33625. DOI: 10.1038/s41598-025-19204-2
https://www.nature.com/articles/s41598-025-19204-2#auth-Keith_R_-Walley-Aff1

Additional resources on genetic causality and sepsis in general
Trinder, M., Walley, K. R., Boyd, J. H. & Brunham, L. R. Causal inference for genetically determined
levels of high-density lipoprotein cholesterol and risk of infectious disease. Arterioscler. Thromb. Vasc
Biol. 40, 267–278 (2020).
https://pubmed.ncbi.nlm.nih.gov/31694394/

Sepsis information guides
https://www.sepsis.org/education/resources/sepsis-information-guides/

About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to contribute to health through innovative therapies in
indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research,
medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment
of renal and ophthalmological diseases, or new HDL vectors used for targeted drug delivery.

Contacts :

ABIONYX Pharma
infos@abionyx.com




2/2